Samsung Bioepis

Nov 27, 2024 | globenewswire.com | Samsung Bioepis

INCHEON, South Korea, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today announced that Kyung-Ah Kim, who has been serving as Executive Vice President and Development Division Leader, has been named as President and Chief Executive Officer of Samsung Bioepis. Kim will succeed Christopher Hansung Ko, who has been appointed to lead Samsung Future Business Division.

Nov 18, 2024 | globenewswire.com | Samsung Bioepis

OPUVIZ™ is one of the first wave aflibercept biosimilars in EuropeOPUVIZ is the second European Commission (EC)-approved ophthalmology biosimilar under Samsung Bioepis and Biogen’s partnershipEC approval based on robust totality of evidence confirming biosimilarity to reference aflibercept in terms of quality, efficacy, and safety INCHEON, South Korea and CAMBRIDGE, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Biogen Inc.

Nov 15, 2024 | globenewswire.com | Samsung Bioepis

INCHEON, South Korea, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for two denosumab biosimilars – OBODENCE™ (60 mg pre-filled syringe) referencing Prolia (denosumab) and XBRYK™ (120mg vial) referencing Xgeva (denosumab) – also known as SB16.

Oct 10, 2024 | globenewswire.com | Samsung Bioepis

This year’s Q4 report newly reflects tocilizumab’s market share and Wholesale Acquisition Cost (WAC) trend analysis after biosimilars launched in Q2Biosimilar Deep Dive section presents US biosimilar adoption and associated cost savings, and how payers and pharmacy benefit managers (PBMs) have optimized their biosimilar strategies for each line of business, based on a survey with 20 payers and PBMs INCHEON, South Korea, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd.

Oct 10, 2024 | finance.yahoo.com | Samsung Bioepis

This year’s Q4 report newly reflects tocilizumab’s market share and Wholesale Acquisition Cost (WAC) trend analysis after biosimilars launched in Q2 Biosimilar Deep Dive section presents US biosimilar adoption and associated cost savings, and how payers and pharmacy benefit managers (PBMs) have optimized their biosimilar strategies for each line of business, based on a survey with 20 payers and PBMs INCHEON, South Korea, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd.